R1 RCM (RCM) Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCM shares.
View RCM analyst ratings or view top-rated stocks.

15 equities research analysts have issued twelve-month price objectives for R1 RCM's stock. Their RCM share price forecasts range from $10.00 to $25.00. On average, they expect the company's stock price to reach $17.44 in the next twelve months. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for RCM or view top-rated stocks among Wall Street analysts.

R1 RCM's stock was trading at $10.95 at the start of the year. Since then, RCM stock has increased by 46.7% and is now trading at $16.06.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our RCM earnings forecast.

R1 RCM Inc. (NASDAQ:RCM) announced its quarterly earnings data on Thursday, February, 16th. The healthcare provider reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.06. The healthcare provider had revenue of $532.80 million for the quarter, compared to analyst estimates of $519.28 million. R1 RCM had a negative trailing twelve-month return on equity of 1.02% and a negative net margin of 4.41%. The business's revenue for the quarter was up 33.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.11 EPS.

ETFs with the largest weight of R1 RCM (NASDAQ:RCM) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Thrivent Small-Mid Cap ESG ETF (TSME), Fidelity Digital Health ETF (FDHT), SPDR S&P Health Care Services ETF (XHS), ERShares NextGen Entrepreneurs ETF (ERSX), Invesco NASDAQ Next Gen 100 ETF (QQQJ), RiverNorth Patriot ETF (FLDZ) and BlackRock Future Health ETF (BMED).

R1 RCM issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.28 billion-$2.33 billion, compared to the consensus revenue estimate of $2.31 billion.

253 employees have rated R1 RCM Chief Executive Officer Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

R1 RCM trades on the NASDAQ under the ticker symbol "RCM."

R1 RCM's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.22%), FMR LLC (1.91%), Sachem Head Capital Management LP (1.78%), American Century Companies Inc. (1.77%), Bank of New York Mellon Corp (1.53%) and State Street Corp (1.18%). Insiders that own company stock include Achi Series Lllp Tcp-Asc, Alex Mandl, Gary Steven Long, John M Sparby, Joseph Gerard Flanagan, Lee Rivas, Michael C Feiner and Richard B Jr Evans.
View institutional ownership trends.

Shares of RCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RCM stock can currently be purchased for approximately $16.06.

R1 RCM (NASDAQ:RCM) has a market capitalization of $6.72 billion and generates $1.81 billion in revenue each year. The healthcare provider earns $-57,600,000.00 in net income (profit) each year or ($0.23) on an earnings per share basis.

The company employs 27,800 workers across the globe.

R1 RCM's mailing address is 401 NORTH MICHIGAN AVENUE SUITE 2700, CHICAGO IL, 60611. The official website for the company is www.r1rcm.com. The healthcare provider can be reached via phone at (312) 324-7820, via email at arahim@r1rcm.com, or via fax at 302-655-5049.